EMA Authorised: Vantobra (previously Tobramycin PARI) (tobramycin) — Pari Pharma GmbH

View source ↗

Summary

EMA authorized Vantobra (tobramycin) for respiratory tract infections including cystic fibrosis; MAH Pari Pharma GmbH; decision date 15/07/2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Respiratory Tract Infections

Drugs mentioned

• Vantobra

Snippet

Status: Authorised. Therapeutic area: Respiratory Tract Infections;Cystic Fibrosis. MAH: Pari Pharma GmbH. Decision date: 15/07/2026